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ABSTRACT
Cervical cancer is the leading cause of cancer mortality in
India, accounting for 17% of all cancer deaths among
women aged 30 to 69 years. At current incidence rates, the
annual burden of new cases in India is projected to increase
to 225,000 by 2025, but there are few large-scale, orga-
nized cervical cancer prevention programs in the country.
We conducted a review of the cervical cancer prevention
research literature and programmatic experiences in India
to summarize the current state of knowledge and practices
and recommend research priorities to address the gap in
services. We found that research and programs in India
have demonstrated the feasibility and acceptability of cer-
vical cancer prevention efforts and that screening strate-
gies requiring minimal additional human resources and
laboratory infrastructure can reduce morbidity and mortal-
ity. However, additional evidence generated through im-
plementation science research is needed to ensure that
cervical cancer prevention efforts have the desired impact
and are cost-effective. Specifically, implementation sci-
ence research is needed to understand individual- and
community-level barriers to screening and diagnostic and
treatment services; to improve health care worker perfor-
mance; to strengthen links among screening, diagnosis,
and treatment; and to determine optimal program design,
outcomes, and costs. With a quarter of the global burden of
cervical cancer in India, there is no better time than now to
translate research findings to practice. Implementation sci-
ence can help ensure that investments in cervical cancer
prevention and control result in the greatest impact. The
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Implications for Practice: Considerable research has been conducted on the prevention of cervical cancer in India. The majority
of studies have focused on the feasibility, acceptability, and impact of secondary prevention of cancer through screening, early
detection, and treatment. Despite this evidence, there have been few government-led public health programs to prevent and
control cervical cancer. The primary goals of this review are to summarize the lessons learned from cervical cancer prevention
research and pilot programs in India and to identify research priorities to facilitate the translation of existing knowledge into pol-
icies and programs that advance cervical cancer prevention.
INTRODUCTION
Cervical cancer is the most common cancer among women
aged 15 years or older in India. Cervical cancer will occur in ap-
proximately 1 in 53 Indian women during their lifetime com-
pared with 1 in 100 women in more developed regions of the
world [1]. In 2010, there were nearly 74,000 new cases of cer-
vical cancer in India. With 38% of cases occurring among
women of reproductive age (15–49 years), the adverse social
and economic impact of cervical cancer on families and com-
munities is considerable [1].
Between 1980 and 2010, little progress was made in re-
ducing cervical cancer mortality in India: 37 women died for
every 100 new cases of cervical cancer in 1980 compared with
32 forevery100newcases in2010 [1].Highmortality ratesare
largely the result of nearly 70% of cervical cancer cases in India
being diagnosed at an advanced stage (stage III or IV) [2].
Fewer than a third of Indian women diagnosed with stage III
cervical cancer survive the first five years after their diagnosis,
and the 5-year survival rate drops to nearly 6% among women
diagnosed with stage IV disease [2].
In contrast to the United States and other high-income
countries, where cervical cancer screening is offered as part of
routine primary care, few large-scale screening programs ex-
ist in India [3]. Moreover, although primary prevention
through human papilloma virus (HPV) vaccination is gaining
acceptance in high-income countries and has been endorsed
by the World Health Organization (WHO), vaccine awareness,
access, and use are very low [4, 5]. However, cervical cancer
prevention efforts appear to be gathering momentum. Coin-
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ciding with the United Nations High Level Summit on Non-
Communicable Diseases in 2011, India’s national government
launched a program to address chronic and noncommunica-
ble diseases (NCDs) that includes screening and treatment of
cervical cancer. Simultaneously, several state governments
decided to do a pilot test of their own NCD prevention efforts.
In this context, we conducted a review of the cervical cancer
prevention research literature and programmatic experi-
ences to summarize the current state of knowledge and prac-
tice and recommend research priorities to facilitate the
translation of existing knowledge into efficient, effective, and
equitable public health action.
METHODS
This paper is based on information gathered from a review of
English-language peer-reviewed publications and gray litera-
ture (including unpublished program reports, white papers,
and conference presentations) on cervical cancer prevention
in India and interviews with individuals involved in the design
and implementation of government-led cervical cancer pre-
vention efforts in the southern state of Tamil Nadu.
The published literature was identified using ISI Web of
Knowledge, PubMed, and Google Scholar using a broad time
frame (1990 to the present). A combination of the following
search terms was used: India, cervical cancer, screening, early
detection, HPV, HPV vaccination, and visual inspection. The
gray literature was identified using keyword search terms in
Google’s search engine, reviewing references of published pa-
pers, and searching Internet-based document repositories.
Papers and reports were reviewed and key information re-
garding methods and findings was abstracted and organized
thematically.
To better understand the translation of knowledge into
practice, we conducted a case study of cervical cancer preven-
tion efforts in the southern state of Tamil Nadu. Data sources
included program reports and presentations, interviews, and
field visits. Nine individuals (public health officials and cancer
preventionexperts)whowere involved inprogramdesignand
implementation were interviewed to ascertain factors that
shaped program design, challenges faced in implementation,
and strategies implemented to overcome those challenges.
Field visits were made to a tertiary hospital where training in
the diagnosis and treatment of cervical cancer is conducted
for health care providers and to a district hospital and primary
health center implementing cervical cancer screening, treat-
ment, and referrals. Interviews and field notes were summa-
rized thematically.
Research on Primary and Secondary Prevention of
Cervical Cancer in India
Our review of the literature on cervical cancer prevention in
India identified 44 peer-reviewed articles focused on the fol-
lowing themes: HPV prevalence and vaccination; perfor-
mance of screening tools; and feasibility, acceptability, and
effectiveness of screening and treatment interventions. Be-
low we summarize the main findings by theme.
Primary Prevention ThroughHPVVaccination
Available data indicate that HPV vaccination is a highly prom-
ising cervical cancer prevention method when used in con-
junction with screening and treatment [6]. Approximately
70%ofcervical cancers in IndiaarecausedbyHPVtypes16and
18, which are targeted by the vaccine [7, 8]. However, there
hasbeen littleempirical researchonthefeasibility,acceptabil-
ity, and effectiveness of HPV vaccination in India. A qualitative
study in the states of Gujarat and Andhra Pradesh identified
three potential mechanisms for vaccine delivery: the existing
national immunization program, adolescent health or cancer
control services, and school- and community-focused cam-
paigns [4, 9]. The study noted that successful introduction of
the vaccine would depend on a communication strategy fo-
cused on raising community awareness, engagement with
community gatekeepers, and advocacy to build political sup-
port for prevention. It also revealed that systems-level chal-
lenges associated with staffing, capacity, and coordination
wouldhavetobeaddressed[4].Other research insouthern In-
dia found that although parents held positive attitudes about
vaccination, they were not in support of vaccinating pre-ado-
lescent girls and felt that vaccination against HPV was more
appropriate once girls had attained puberty [5].
Public provision of HPV vaccination has been debated in
the mainstream press and in academic journals [4, 10 –18].
Women’s health activists and researchers in India have ques-
tioned the appropriateness of the HPV vaccination in light of
limited data on safety and efficacy, the high cost, and the un-
certain cost-effectiveness of the vaccine. They have argued
that the government should focus on promoting awareness
and ensuring access to comprehensive reproductive and sex-
ual health services, including cervical cancer screening and
treatment [14]. Others have challenged investments in HPV
vaccination by disputing the data on India’s cervical cancer
burden, arguing that incidence rates are in fact on the decline
in the country [15]. The deaths of four adolescent girls en-
rolled in a government-approved demonstration project in
Gujarat and Andhra Pradesh escalated the controversy. Al-
though an expert panel later concluded that the deaths were
unrelated to the vaccine [9], the investigation revealed ethical
violations related to the process of informed consent [11].
HPV vaccine debates in India raise several issues for con-
sideration in future vaccination efforts. First is the need for
systems to monitor, report, and respond to postvaccination
adverse events. The Gujarat and Andhra Pradesh study found
that although guidelines were available for postimmunization
adverseeventmanagement,oftentheywerenot followed[4].
Additionally, the widely differing interpretations of the data
onHPVvaccinesafetyamonghealthactivists, clinicians,public
health practitioners, and journalists suggests that a more ro-
bust communication strategy is needed to disseminate evi-
dence in support of vaccination. Research should identify
effective ways to communicate information regarding the
vaccines, including a focus on adolescent girls, partial efficacy,
and the need for cervical cancer screening in adulthood.
Finally, cost and cost-effectiveness remain important con-
siderations for India’s HPV vaccination policy. A mathematic
modeling study informed by empirical data from India found
that pre-adolescent vaccination for HPV types 16 and 18 can
reduce lifetime cervical cancer risk by 44%, assuming 70% vac-
cine coverage, and is more effective than screening alone, re-
gardless of screening test, screening frequency, and target
age groups [19]. Combining vaccination with screening was
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cost-effective according to WHO benchmarks for developing
countries at a vaccine cost of US$2 per dose or less.
The Indian market price of the vaccine is approximately
US$40 per dose. In 2013, the GAVI Alliance announced that it
would offer the HPV vaccine at US$4.50 per dose to countries
with a gross national income per capita below or equal to
US$1520 [20]. The estimated total cost of vaccination per girl,
taking into account three doses and vaccine delivery costs, is
US$20.70 [21]. Eligible countries (of which there are 57, in-
cluding India) can apply for support to introduce the vaccine
nationwide or to conduct pilot projects that will enable them
to prepare for national implementation. In light of the global
evidence on HPV vaccination, pilot testing the vaccine and
gathering empirical data on vaccine delivery costs and cost-
effectiveness can significantly advance cervical cancer pre-
vention efforts in India.
Secondary Prevention Through Screening
Secondary prevention through screening and treatment of
precancerous and early stage cancerous cervical lesions can
prevent disease progression and reduce subsequent morbid-
ity and mortality. Substantial declines in cervical cancer inci-
dence and mortality in high-income countries such as the
United States have been attributed to screening. However,
screening approaches used in high-income countries (namely,
the annual Papanicolaou smear test) may not be appropriate
in low- and middle-income countries where establishing labo-
ratory infrastructure, training personnel such as cytotechni-
cians and pathologists, and implementing continuous quality
assurance procedures have proven difficult [22]. Conse-
quently, research has focused on evaluating visual inspection-
based methods that use existing (or minimal additional)
human resources and require less training and fewer clinic vis-
its (Table 1).
Accuracy of Screening Tests
Over the past decade, 14 studies have been conducted in India
to evaluate the accuracy and effectiveness of cervical cancer
screening [23–34]. Studies have compared the specificity and
sensitivity of visual inspection with acetic acid (VIA) or Lugol’s
iodine (VILI) and the Papanicolaou test and HPV DNA testing.
These approaches have been implemented by health workers
such as auxiliary nurse midwives (Table 2). The majority of
these studies were cross-sectional in design and involved ei-
ther community- or hospital-based samples [23–32, 35]; two
studies were randomized controlled trials [33, 36–38]. To de-
termine test sensitivity and specificity, most studies per-
formed colposcopy for all participants and biopsy of
abnormalities if indicated; in some, the colposcopist was
blinded to the initial screening test results [24, 26, 27].
Salient findings of Indian studies on screening test perfor-
mance are summarized in Table 3. Overall, research in India
suggests that VIA and VILI have comparable sensitivity and
specificity toPapanicolauoandHPVDNAtest-basedscreening
(Table 3). Studies have found that the sensitivity to detect cer-
vical intraepithelial neoplasia (CIN) grade 2 or higher (CIN2)
is similar for VIA (range 64.5%–89.5%) and VILI (range 64.5%–
100%) compared with Papanicolaou test (range 52.6%–
62.3%). Research has found test specificity of VIA (76.4%–
84.2%) to be lower than that of VILI (85.4%–93.4%) and HPV
testing (80.7%–81.3%). Cytology testing has the highest spec-
ificity (76.1%–99.1%) [23–32, 35].
Studies have indicated that visual inspection-based ap-
proaches have lower test sensitivity when used with older
women because of the migration of the transformation zone
into the endocervical canal [37, 39]. Consequently, different
screening strategies may be needed depending on the age
group of the target population.
An advantage of visual inspection-based approaches is
that the immediate availability of screening results provides
the opportunity to conduct a biopsy or offer treatment at the
same visit (a screen-and-treat approach), reducing the likeli-
hood of loss to follow-up. That said, there is a risk for over-
treatment in this context given that the specificity of visual
inspection-based approaches is lower than that of the Papani-
colaou test or HPV DNA testing. Although there is no clear ev-
idence of harm arising from overtreatment [40, 41], some
researchers contend that using the screen-and-treat ap-
proach entails risks that may only become apparent with lon-
ger follow-up [42]. The feasibility and effectiveness of the
screen-and-treat method should be examined further in a pa-
tient program.
In conclusion, decisions regarding which screening strat-
egy to use will largely depend on context, including the avail-
ability of infrastructure and human and financial resources.
Studies on screening methods in India indicate that visual in-
spection-based approaches are feasible and reasonably accu-
rate when compared with methods such as the Papanicolaou
test and HPV DNA testing. However, training and quality as-
surance are especially important to ensuring acceptable test
performance levels when using visual inspection. Thus, a key
challenge is tocreateasystemthat is capableofeffectivelyde-
ploying the selected screening strategy. Establishing such a
system and initiating screening can lay the foundation for the
introduction of more optimal primary screening tests in the
future.
Screening Coverage and Treatment Linkings
The effectiveness of screening is determined not only by the
accuracy of the screening test, but also by screening coverage
and linkages to diagnostic and treatment services. Several
community-based studies have tracked participation and re-
tentionratesbyfirstenumeratingalleligiblewomeninthetar-
get communities [25, 33, 36] or using census lists to determine
the number of women eligible [29]. Even in the context of
well-resourced studies, achieving high levels of screening par-
ticipation and adherence to diagnostic and treatment recom-
A mathematic modeling study informed by empirical
data from India found that pre-adolescent vaccina-
tion for HPV types 16 and 18 can reduce lifetime cer-
vical cancer risk by 44%, assuming 70% vaccine
coverage, and is more effective than screening alone,
regardless of screening test, screening frequency,
and target age groups. Combining vaccination with
screening was cost-effective according to WHO
benchmarks for developing countries at a vaccine
cost of US$2 per dose or less.
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mendations—without which it is difficult to justify screening—
has been a challenge.
Studies that successfully recruited and retained partici-
pants in screening and treatment engaged with women, hus-
bands, and family members; offered appointments and
screening cards to women; and involved local government
health workers and community leaders in mobilization efforts
(Table 4) [25, 33, 36]. In Dindigul district, Tamil Nadu, accessi-
bility was further enhanced by offering screening services at
primary health centers, municipal offices, schools, women’s
clubs, and homes [33]. The study screened 63% of eligible
women.
The importance of community engagement is under-
scored by the Community Access to Cervical Health study
(CATCH), which despite using a fairly comprehensive ap-
proach involving community liaisons to promote screening,
house-to-house visits, and transportation to a tertiary screen-
ing center, had among the lowest participation rates of pub-
lished Indian studies: nearly three in five eligible women
(59.4%)refusedtoundergoscreening[29].Reasons for refusal
included lack of symptoms indicating a health problem; fear of
the tests, the pelvic examination, and a cancer diagnosis; and
community gossip and misconceptions.
Similar reasons for screening refusal were reported by
Basu et al. [43] in their Kolkata study. Additionally, they found
that some women were unable to attend screening clinics be-
cause of household responsibilities, family problems and ill-
nesses, and refusal of husbands or other relatives to grant
permission.A fewwomenwhomade it to theclinic leftprior to
being screened because of apprehension about the process
(after seeing the screening instruments), the long waiting
times, and the presence of male doctors.
Facilitators of and barriers to patient adherence to diag-
nostic and treatment recommendations were generally simi-
lar to those for screening. Loss to follow-uptendedtobe lower
in the case of more advanced disease, but did not vary consis-
tently by location of diagnostic and treatment service provi-
sion [29, 33, 34, 36]. In the Dindigul study, trained nurses used
a screen-and-treat approach for most precancerous lesions
and referred women requiring loop electrosurgical excision
procedure or cold knife conization or with invasive cancers to
a tertiary center [33]. The study documented high loss to fol-
low-up among women who did not choose to undergo screen-
ing and treatment at the same visit: 53% of women who were
eligible for the screen-and-treat approach but decided to first
consult their husband or other family members did not return
for treatment. Diagnostic and treatment completion rates
among women referred to a tertiary center were 80% and
75%, respectively [33]. In the Osmanabad, Maharashtra, trial,
85% of those referred to a central clinic for diagnostic and
treatment procedures adhered to recommendations [36].
The CATCH study reported the lowest acceptance of diagnos-
Table 1. Overview of primary screening tools for cervical cancer
Screening Testa Strengths Limitations
VIA:
Acetic acid is applied to the cervix to identify
precancerous and cancerous lesions.
Process is often aided by amagnification tool.
• Requires less training (5–10 days) than
other methods
• Cheaper than cytology/HPV testing
• Immediate results
• Potential for immediate treatment (“screen
and treat”)
• Variable (low to moderate) sensitivity
and specificity for CIN2
• Possibility for overtreatment
• Acetic acid must be prepared directly
before screen
• Inappropriate for older women (50
years) because of change in cervix
position
VILI:
Lugol’s iodine is applied to the cervix to
identify precancerous and cancerous lesions.
Process is often aided by amagnification tool.
• Requires less training (5–10 days) than
other methods
• Cheaper than cytology/HPV testing
• Immediate results
• Potential for immediate treatment (“screen
and treat”)
• Has a 1 month shelf life
• Variable (low to moderate) sensitivity
and specificity for CIN2
• Possibility for overtreatment
Cytology (Papanicolaou smear): • High specificity for CIN2 • Relatively low sensitivity
Sample of cells taken from transformational
zone of the cervix. Sample is smeared onto a
glass slide. Slide is sent to laboratory for
reading by a cytologist.
• Requires laboratory and specialized
technicians
• Lag in test results can contribute to
loss to follow up and delay treatment
HPV DNA test:
Sample of cells taken from the cervix by a
provider or thewoman herself. Sample is sent
to laboratory for analysis by trained
technicians.
• High specificity and sensitivity for HPV
infection
• Requires minimal training
• Woman can self-collect sample
• Has to be followed by a test for
dysplasia
• Requires laboratory and trained
technicians
• Lag in test results can contribute to
loss to follow up and delay treatment
aAdapted from 55, 56.
Abbreviations: CIN2, cervical intraepithelial neoplasia grade 2 or higher; HPV, human papilloma virus; VIA, visual inspection with acetic acid; VILI,
visual inspection with Lugol’s iodine.
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tic and treatment procedures, with 34% of women refusing
colposcopy and biopsy after a positive screening test [29]. The
relative role of factors such as cancer stigma, accessibility of
services, and family support in shaping diagnostic and treat-
ment adherence needs to be explored further.
The translation of evidence on cervical cancer screening and
treatment approaches into effective prevention programs de-
pends on a sound understanding of factors operating at the level
of the individual, community, and health system that influence
women’saccess to information/education, screening,diagnosis,
and treatment. Further investigation of these factors and evalu-
ationof strategies to improveserviceuptakecan facilitate future
program planning and implementation.
Quality of Service Provision
To date, researchers have assessed the quality of cervical can-
cer prevention services primarily in terms of screening test
performance,andqualityassurancehas focusedontrainingof
health care providers (Table 5). Although studies have found it
feasible to train frontline health workers such as auxiliary
nurse midwives and staff nurses to implement visual inspec-
tion-based screening and treatment of precancerous lesions
using cryotherapy, concerns have been raised about the qual-
ity and consistency of service provision [36, 44]. Auxiliary
nursemidwives intheOsmanabadstudyreceivedthreeweeks
of trainingoncervical samplecollection,VIA,andcryotherapy,
but poor concordance on VIA results between the master
Table 2. Health care workers trained to perform cervical cancer screening and treatment in studies in India




(curriculum) Frequency of retraining
Sankaranarayanan et al., 2004
(Dindigul, Tamil Nadu) 33
Nurses (3 years of nursing education
after 10 years of schooling)
Training on VIA, colposcopy
and cryotherapy
3 weeks (IARC) Every 4 months
Physicians (medical officers) Training on VIA, colposcopy,
cryotherapy, LEEP
NS NS
Surgeons Training on cold knife
conization
NS NS
Pathologists, laboratory technicians Retraining on biopsy specimen
processing and reporting
NS NS
Sankaranarayan et al., 2004
(Mumbai, Maharashtra; Jaipur,
Rajasthan; Kolkata, West Bengal;
Thiruvananthapuram, Kerala) 35
Female health workers with varying
educational backgrounds
(registered nurses, cytotechnicians,
university graduates in science and
arts, high school graduates)






15 days (IARC) 1 day every 4–6 months
Pathologists, laboratory technicians Retraining on biopsy specimen
processing and reporting
1 day refresher NS
Sankaranarayan et al., 2005
(Osmanabad, Maharashtra) 36
Auxiliary nurse midwives Training on VIA, cell sampling
for cytology and HPV,
cryotherapy
3 weeks (IARC) 2 brief refreshers over 4
years
Physicians Training on colposcopy,
cryotherapy, and LEEP
(IARC)
Pathologists Retraining on biopsy reporting 2 weeks (TMC) Refresher after 9 months
Laboratory technicians Training on processing and
reporting cytology slides,
biopsy, HPV test
3 months (TMC) Refresher after 9 months
Bhatla et al., 2009 (Faridabad district,
Haryana) 25
Auxiliary nurse-midwives Training on VIA and VILI, cell
sampling for cytology
(IARC) Retrained, but frequency
not specified
Physicians Training on cryotherapy, LEEP (IARC)
Deodhar et al., 2012 (Solapur district,
Maharashtra) 27
Nurses Retraining on VIA, cell
sampling for cytology and HPV,
cryotherapy
NS (IARC) Every 6 months after
retraining
Physicians (colposcopists) Retraining on colposcopy,
cryotherapy, and LEEP
NS (IARC) Every 6 months after
retraining
Physicians (pathologists) Retraining on cytology, biopsy
reporting
NS (IARC) Every 6 months after
retraining
Cytotechnicians Retraining on processing and
reporting cytology slides,
biopsy
NS (IARC) Every 6 months after
retraining
Gravitt et al., 2010 (Medchal Mandal,
Andhra Pradesh) 29
Physicians (gynecologists) VIA, VILI, HPV DNA, colposcopy NS NS
Abbreviations: HPV, human papilloma virus; IARC, International Agency for Research on Cancer; LEEP, loop electrosurgical excision procedure; NS,
not specified; TMC, Tata Memorial Center, Mumbai; VIA, visual inspection with acetic acid; VILI, visual inspection with Lugol’s iodine.
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Table 3. Summary of Indian studies on accuracy of cervical cancer screening tests
Primary
screening test Study location Sample Study design
Sensitivity and specificity (respectively)







Andhra Pradesh 29 Population-based n
2,331 25 years
Cross-sectional 26.3%, 6.4% 36.4%, 6.5%
Solapur District 27 Population-based n
5,519 30–49 years
Cross-sectional 64.5%, 84.2%













Kolkata 23 Population-based n
5,881 30–64 years
Cross-sectional 55.7%, 82.1%










Faridabad District 25 Population-based n
3,000 25–59 years
Cross-sectional No sensitivity, 86.1%

















VILI Solapur District 27 Population-based n
5,519 30–49 years
Cross-sectional 64.5%, 85.5%
IARC multicenter 35 Population-basedN
104,061 26–65 years
















Cytology (Pap Smear) Andhra Pradesh 29 Population-based n
2,331 25 years
Cross-sectional 63.2%, 76.2% 81.8%, 76.1%








Kolkata 23 Population-based n
5,881 30–64 years
Cross-sectional 29.5%, 92.3%










Faridabad District 25 Population-based n
3,000 25–59 years
Cross-sectional No sensitivity, 94.8% (ASCUS) 97.2% (LSIL)









Cross-sectional 36.6%–72.3% (ASCUS) 87.2%–98.6%
(LSIL)
(continued)
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trainer and the nurses led to two rounds of refresher training
[36].
Prescreening and postscreening procedures, including in-
formed consent for screening and postscreening counseling
and monitoring patient follow-up rates for diagnostic confir-
mation and treatment, are important components of quality
assurance that have not been discussed extensively in the re-
search literature. It is unclear whether studies used electron-
ic- or paper-based health information systems to monitor
participant retention and follow-up, whether any specific ac-
tions were taken to minimize loss to follow-up, and which ac-
tions were most effective in promoting patient retention.
Identifyingbestpractices inqualityassurance isahighpriority.
Impact of Screening onMorbidity andMortality
Three large-scale randomized controlled trials in India have
foundthat screeningcanreducecervical cancermorbidityand
mortality [34, 37, 38]. In Dindigul, a single round of VIA-based
screening led to a 25% reduction in cervical cancer incidence
anda35%reduction inmortalityover sevenyearsof follow-up
[37]. Similar results (31% reduction in mortality) were re-
ported recently by a trial that offered multiple rounds of VIA-
based screening in Mumbai, Maharashtra [34]. A third
randomized controlled trial in Osmanabad found that a single
round of HPV testing led to reductions in mortality, whereas
VIA and cytology did not [38]. Although screening uptake and
treatment adherence did not differ between the study arms,
questionshavebeenraisedaboutwhetherdifferences indiag-
nostic and treatment procedures across study arms may ex-
plain the observed outcomes [45].
Overall, data from India indicate that VIA, when offered
under the controlled conditions of a trial with systems for fol-
lowing-up with women whose screening is positive and high
adherence to diagnostic and treatment recommendations,
leads to significant declines in cervical cancer mortality within
a decade of intervention initiation, lending further support to
the rationale for investment in secondary prevention. That
said, the effectiveness of screening in less controlled pro-
gramsandprogramswithpotentially fewerresources remains
unclear.
In Dindigul, a single round of VIA-based screening led
to a 25% reduction in cervical cancer incidence and a
35%reduction inmortalityoversevenyearsof follow-
up. Similar results (31% reduction in mortality) were
reported recently by a trial that offered multiple




test Study location Sample Study design
Sensitivity and specificity (respectively)





HPV DNA test Andhra Pradesh 29 Population-based n
2,331 25 years
Cross-sectional 84.2%, 81.3% 100%, 80.72%

























Abbreviations: ASCUS, atypical squamous cells of undetermined origin; CIN, cervical intraepithelial neoplasia; HSIL, high-grade squamous
intraepithelial lesion; IARC, International Agency for Research on Cancer; LSIL, low-grade squamous intraepithelial lesion; RCT, randomized
controlled trial; VILI, visual inspection with Lugol’s iodine.
Table 4. Strategies used to promote screening in India
• Mobilizationefforts ledbylocalhealthworkers(medicalofficers,communityhealthworkers)whoareknownandrespectedinthecommunity
• Involvement of community leaders (e.g., panchayat village government, women’s group members)
• Use of advertising campaigns through print and other media
• Promotion of “champions” such as cancer survivors or local celebrities
• Education of women, husbands, and families
• Recruitment through home visits by known health care workers
• Provision of screening appointments and informational cards
• Provision of screening and treatment services at locations close to the community
• Provision of screening by female health care providers
• Provision of screening and treatment in one visit
• Provision of transportation to referral clinic for diagnostic and treatment services
• Minimization of waiting times
Sources: 25, 33, 48, 57, 58.
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Cost Effectiveness of Screening
Modeling studies using primary and secondary research data
from India indicate that cost-effectiveness of vaccination is in-
fluenced by vaccine cost, efficacy, coverage, and duration of
protection, whereas cost-effectiveness of screening depends
on the linkages between screening and treatment, number of
clinic visits, and laboratory infrastructure required [19, 46].
Strategies that targeted women in their mid-30s were the
most cost-effective (compared with those that screened
women less than 30 years old or more than 45 years old).
The Osmanabad randomized controlled trial, which esti-
mated screening costs and cost-effectiveness, found that pro-
gram implementation expenses (e.g., for monitoring patient
recruitment and follow-up) were substantial—as high as one
fifth of the total costs in the VIA arm [47]. VIA was the least ex-
pensiveoption,detecting7.5CIN2/3casesper1,000eligible
women and costing $522 per case detected (compared with
no screening), whereas cytology detected 10 cases per 1,000
and cost $659 per case. HPV DNA testing was nearly twice as
expensive as cytology and detected fewer cases. Another
modeling study recommended screening adult women two to
three times per lifetime in addition to administering pre-ado-
lescent vaccination, and found that this combination (assum-
ing 70% coverage for both strategies) yielded a 56% to 63%
reduction in cancer incidence [19].
Program data are needed to better understand cost and
cost-effectiveness of available prevention strategies. Moni-
toring and evaluation of pilot programs in different settings
(e.g., rural vs. urban) can yield important insights about the
choice of prevention strategies. Finally, analyses should also
account for treatmentcostsand longer-termbenefits in terms
of life years saved.
Translation of Research Into Practice
Tamil Nadu State’s cervical cancer screening and treatment
program designed and implemented by the World Bank-sup-
ported Tamil Nadu Health Systems Project (TNHSP) is among
the few examples of large-scale government-led prevention
efforts in India. In 2007, Tamil Nadu launched a pilot cervical
cancer screening program in two predominantly rural dis-
tricts, Theni and Thanjavur, to identify challenges and poten-
tial solutions prior to a state-wide scaling up of the program
[48]. The goals of the cervical cancer program were to raise
community awareness, promote early detection by offering
routineVIA/VILI-basedscreeningto30- to60-year-oldwomen
seeking public health services, and offer appropriate referrals
and treatment (Table 6).
The pilot program, led by a senior bureaucrat and de-
signed by technical experts, received administrative support
from the government of Tamil Nadu, political backing, and the
necessary financial resources. A team of public health physi-
cianswhowere taskedwith implementationcoordinationand
oversight and staff nurses who were trained to provide NCD
prevention services including VIA/VILI, and data management
personnelwerehired.Consultationswereheldwithexperts in
NCD screening, diagnosis, and treatment to finalize clinical
protocols and operations manuals, and a detailed capacity-
building process was developed to train and equip staff to im-
plement theprogram. Inaddition, theprogramcommissioned
an external monitoring and evaluation and cost analysis of the
program.
Between 2007 and 2010, the program screened nearly
500,000 women, which translates to about 74% of the eligible
population [48]. However, VIA/VILI positivity was lower than
reported in the literature: 5.4% in Thanjavur and 2.6% in Theni
Table 5. Quality assurance methods
Task Personnel Methods of quality assurance
Community mobilization Health workers, primary health care nurses/staff,
study staff, local resource persons
• None
Informed consent Female health workers • Training of staff 25, 27, 33
Training Health workers (auxiliary nurse midwives,
nurses), technicians, doctors
• Training and periodic refresher training 36
Screening implementation Community health workers, gynecologists, nurses • Comparison of different primary screening
modalities implemented by different health
workers who are blind to results of other
tests 23 or by same health worker 27
• Colposcopy/biopsy conducted by a
gynecologist blind to the results of the
primary screening test 24
Diagnostic confirmation Physicians and laboratory technicians • Quality control checks by master trainers/
experts 36
• Review of a random sample of slides by
master trainers/experts 36
Counseling Physicians 29, nurses 37 • None
Treatment Physicians • Receipt of second opinion
• Quarterly review of treatment outcomes
(Tamil Nadu Health Systems Project)
Data collection Staff nurses, statisticians • Establishment of health information system
• Training, queries, and monitoring by
statistical assistants and district level
managers (Tamil Nadu Health Systems
Project)
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compared with approximately 15% to 20% in published Indian
studies [35, 39, 48]. Follow-up rates were also relatively low,
with approximately half of women with a positive screen un-
dergoing diagnostic investigations. The program detected
relatively few precancerous lesions (103 CIN2/3 lesions) com-
pared with invasive cancers (887), although this may be in part
because the population was largely unscreened. Notably, the
overall proportion of women treated was low; only 13% of
women needing treatment received it through the program
[48].
A number of implementation challenges are likely to have
led to these program outcomes (Table 6). Efforts to mobilize
women to undergo screening were constrained by a limited
evidence base to guide information, education, and commu-
nication efforts and outreach, which was initially carried out
by contractual workers hired by nongovernmental organiza-
tions,was inconsistentandoftenofpoorquality. Thehighcov-
erage achieved by the program despite these limitations was
likely theresultofTamilNadu’s strongprimaryhealthcaresys-
tem combined with the concerted efforts of the staff of the pi-
lot program. However, that a large proportion of women did
not return for diagnostic and treatment services suggests the
existenceofother individual-, community-andhealthsystem-
level barriers such as lack of transportation or resources to
travel to higher-level facilities for diagnostic confirmation and
treatment, lackof familial support, cancer-relatedstigma,and
inadequate referral systems. TNHSP subsequently hired a
communications agency to conduct formative research and
develop an information, education, and communication plan.
However, administrative issues prevented the deployment of
the plan within the pilot implementation period, and the ef-
fectiveness of the information, education, and communica-
tion strategy has not been evaluated.
Program outcomes such as relatively low VIA/VILI positiv-
ity, high loss to follow-up, and low levels of treatment provi-
sion were likely the result of several factors within the health
system.Ensuringadequate, consistent, andhigh-quality train-
ing is one factor. Staff nurses received two days of training on
VIA/VILI, which may not have been sufficient. In fact, similarly
low VIA/VILI positivity was reported in Bangladesh, highlight-
ing the need for refresher training [49]. Moreover, training
quality could have been improved by greater standardization
of the number of VIA/VILI tests done, the number of positive
cases observed, and structured post-training assessments of
knowledge and skills. Anecdotal evidence also suggests that
refresher training may have been needed to increase physi-
cian confidence to conduct cryotherapy, conization, and loop
electrosurgical excision procedure and to promote adherence
to program protocols.
Several additional human resource-related issues may
have also influenced the level and consistency of program im-
plementation. Frequent changes in personnel at the local, dis-
trict, and state levels because of transfers and staff attrition
meant that program-related knowledge and experiences had
to be continuously reestablished. In addition, accuracy of data
reporting may have been reduced because nurses felt pres-
sured by the pilot program’s target-oriented approach; each
center had fixed targets for the number of women they had to
screen each month regardless of the sociodemographic pro-
file of the communities they served. In many health centers,
the newly hired nurses were tasked with provision of routine
healthcareservices,despitehavingbeenrecruitedspecifically
for the NCD prevention program. This situation was exacer-
bated because existing health department staff were reluc-
tant to provide NCD-related services. Finally, difficulties in
ensuring the availability of sufficient numbers of pathologists
and obstetrician/gynecologists may have contributed to de-
lays in reporting of biopsy results and treatment provision.
These challenges were further compounded by infrastruc-
tural and logistic issues such as lack of availability of drugs and
reagents (e.g., drugs to treat reproductive tract infections)
and infrastructural deficiencies (e.g., lack of electricity, which
made visualization of the cervix difficult).
Perhaps the most important challenges faced by the
TNHSP pilot program had to do with the establishment of
mechanisms to facilitate patient follow-up and quality assur-
ance. Although screening was promoted at all primary care fa-
cilities, diagnostic confirmation and treatment were offered
only at select secondary and tertiary facilities where related
infrastructureandhumanresourceswerealreadyavailable. In
this scenario, communication and coordination of referrals
between levels of the health care system were especially diffi-
cult. Moreover, the reliance on “village link volunteers” to fa-
cilitate patient follow-up may have been ineffective because
these individuals were hired by local nongovernmental orga-
nizationsanddidnothavesufficient familiaritywith thehealth
system. The volunteers had a poor rapport with existing
health department staff such as the village health nurses, and
they were offered only an honorarium (which was not always
paid on time by their nongovernmental organization em-
ployer). Inaccurate and inconsistent data reporting such as in-
complete or false addresses and lack of clarity regarding the
definition of clinical terms and outcomes also hampered fol-
low-up of patients and program monitoring, preventing
timely responses to program deficiencies.
Similar toearly stagescreeningprograms inother low-and
middle-income countries, the TNHSP pilot emphasized
strengthening the health care infrastructure and training
healthcareworkers todelivercancerpreventionservices [49].
Establishing a comprehensive quality assurance program,
identifying strategies to promote communication and coordi-
nation between different levels of the health care system, and
strengthening systems to facilitate identification and moni-
toring of cases for follow-up are issues that need to be ad-
dressed in the next phase of the program [50–52].
Recognition of these challenges has led to a range of re-
sponses in the design of the statewide scale up of the program
(Table 7). These include the provision of refresher training for
all health care workers; the introduction of an electronic
health information system, with patient records accessible at
different levels of the health care system; and the use of novel
strategies to improve patient follow-up, such as cell phone re-
mindercalls.Ongoinganalysesofdatacapturedbythis system
are shared by state-level program officials with district-level
staff through monthly videoconferences and with communi-
ty-level staff (mainly nurses) through weekly meetings at the
district hospital. A variety of quality assurance methods, in-
cluding facility checklists, exit interviews, and structured ob-
servations, are being used.
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The TNHSP pilot program has demonstrated the feasibility
and acceptability of introducing cervical cancer prevention into
the Indianpublichealth systemwhenthere isadequateandcon-
sistent political and administrative support. It has also high-
lighted several implementation challenges related to service
uptake and program delivery. Although few conclusions can be
drawn about the outcomes and impacts of the pilot program
giventhelackofevaluationdata, thesepilotexperiencesandsys-
tematicdocumentationandanalysisofthescale-upprogramcan
provide important insights for future prevention efforts in the
country. Experiences in countries such as Zambia [51] and El Sal-
vador [52] have revealed that focused efforts to improve quality
of service provision, including follow-up rates, entail a strong
commitment to quality improvement, dedicated resources, and
adefinedmethodology.Basedonthesecriteria,TNHSPiswellpo-
sitioned to successfully improve cervical cancer prevention




celerated global efforts to prevent and control cervical cancer. In
India, qualitative research has identified factors that influence
the feasibility and acceptability of HPV vaccination. Cross-sec-
tional studies and randomized controlled trials have shown that
visual inspection-basedscreeningapproachescanachievesensi-
tivity and specificity comparable to that of cytology-based
screening, that this screening can be implemented by frontline
health workers, and that it can reduce cervical cancer incidence
and mortality. The TNHSP pilot program has demonstrated the
feasibilityofapplyingresearchinsightstopublichealthpolicyand
practice. However, our review of research and program experi-
ences has revealed a number of critical gaps in the translation of
the available evidence for public health action. Implementation
science, which may be defined as research that supports the up-
take, implementation, and sustained use of evidence-based in-
terventions in routine practice and program settings, can help
bridge these gaps [53].
Implementation science can provide evidence on program
effectiveness,efficiency,andsustainability [54], and involves the
use of a wide range of methods, data sources, and study designs.
Forexample, implementationscienceresearchcanentail theuse
ofdata fromprogrammonitoringandevaluationsystemstobet-
terunderstand factors thatexplain thegapbetweendesiredand
observed program outputs and outcomes. It can involve experi-
mental and quasiexperimental approaches to assess the com-
parative advantages and cost-effectiveness of different
intervention packages. Alternatively, it can use qualitative and
quantitative methods to identify ways to enhance service up-
take, improveimplementationqualityandefficiency,andensure
that a continuum of services is being delivered.
Below, we put forth implementation science priorities for
advancing cervical cancer prevention and control in India:
● Understanding individual and community-level barriers
to uptake of screening, diagnostic, and treatment services can
lead to the identification and testing of strategies to increase
program coverage and improve outcomes. For example, re-
search is needed to determine how best to communicate the
benefits and limitations of available prevention and control
strategies to key stakeholders such as women and their hus-
bands and to explore the role of cultural beliefs, stigma, gen-
der inequities, and other factors in shaping health care
decisions. Available evidence suggests that women who are
older and have fewer socioeconomic resources are less likely
to undergo cervical cancer screening and to have poorer out-
comes. Program monitoring data can be analyzed to assess
whether specific groups of women are underserved and why,
leading to appropriate programmatic responses.
● Improving health care worker performance by identifying
effective methods for training, supporting, and supervising pro-
viders is a priority. This includes the use of quality improvement
tools such as “plan, do, study, act” cycles, telemedicine, simula-
tion-based training, and financial and nonfinancial incentives.
● Strengthening links among screening, diagnosis, and
treatment is critical to program success. The TNHSP program
integrated cervical cancer prevention into a broader initiative
focused on NCDs, with screening taking place at the primary
health care level and diagnostic confirmation and treatment
taking place at the secondary and tertiary levels. Although
screening coverage was high, patient follow-up rates for diag-
nostic confirmation and treatment were poor. Implementa-
tion science research can be used to identify and evaluate
strategies to increase patient retention and improve commu-
nicationandcoordinationacross levelsofthehealthcaresystem.
Table 6. Tamil Nadu Health Systems Project cervical cancer program by level of care
Level Services provided Method Health institutions Staff (in pilot) Staff (in scale up)









disease program staff nurse
Secondary Further evaluation and
diagnosis




(specifically trained for the
task)
Same as in pilot
Tertiary Treatment Depends on severity Government medical
colleges and hospitals
Specialists Same as in pilot
District/region Monitoring and
evaluation
Not applicable Not applicable Cancer control officers Statistical assistants, regional
medical officers, regional
consultants
Source: Tamil Nadu Health Systems Project.
Abbreviations: VIA, visual inspection with acetic acid; VILI, visual inspection with Lugol’s iodine.
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Potential strategies include the provision of transportation, em-
ployment of patient navigators, and/or the use of mobile com-
munication technologies.
● Determining optimal program design, outcomes, and
costs is important given the number of competing public
health priorities facing the Indian government, including the
growing burden of NCDs such as diabetes, hypertension, and
cancer. In their 2013 guidance note, WHO emphasized the im-
portance of taking a comprehensive approach to cervical can-
cer prevention and control by implementing vaccination
programs as well as screening and treatment in conjunction
with education and social mobilization at appropriate points
Table 7. Lessons learned from implementation of a pilot cervical cancer screening program in Tamil Nadu
Challenges during pilot implementation Actions to address challenges during scale up
Communitymobilization
• Lack of strategic mobilization plan that detailed formative research,
staff/community involved, methods, and levels of outreach, which
adversely affected screening coverage
• Agency hired to conduct formative research and develop
information, education, and communication strategy
and materials
• Difficulty building awareness and buy-in to screening program in
rural areas
• Use of multipronged strategy (television, radio, print,
etc.)
• Awareness created at four levels: clinical, school,
community, and workplace
• Advertisements targeted at all eligible women and men
Project staffing/training
• Task shifting: Medical officers initially charged with screening, but
tasks eventually fell to nurses and even counselors
• Appointment of staff nurses specifically for NCD
• Role creep: Nurses engaged in provision of routine services rather
than services related to NCD
• NCD training for all nurses to keep services running in
absence of NCD staff nurse
• Village level volunteers (contractual workers given honorarium)
ineffective in mobilizing women and doing follow-up
• Reliance on village health nurses (health department
staff) to mobilize women and support follow-up
• Staff turnover at all levels of care • Regular payment of salaries and building staff
relationships
• Subjective nature of screening tests, making quality assurance
difficult and leading to large number of false positive results
• Expanded training program with adequate exposure to
positive and negative cases
• Periodic refresher trainings
Procurement/maintenance
• Lack of regular supply of drugs/reagents • Separate budget created and approved for purchases
• Malfunctioning equipment • Central procurement by NCD coordinating site to ensure
timely supply of drugs and other consumables
• Ensure staff trained on stocking equipment and
monitoring orders
• System to monitor and maintain equipment
Protocols and guidelines
• Nonadherence to protocols • Simplification and refinement of protocols and reduced
number of conditions requiring referrals
• Reluctance by staff to document and report service provision • Staff supported to estimate case load based on local
conditions and to monitor actual case load
• Inability to meet targeted screening goals
Data collection
• Poor data quality • NCD staff nurse responsible for data entry
• Lack of analysis/corrections of reports at district level • Dedicated statistical assistant to monitor data quality
and compilation
• Incorrect information provided by patients (i.e., addresses) • Routine reporting of data through monthly
videoconferences
Access to treatment
• Few centers equipped to do colposcopy and biopsy • Village health nurses responsible for following up with
patients and facilitating links to tertiary level services
• Poor follow up of patients needing diagnostic and treatment
services; small proportion (13%) of women obtained treatment
• Coordination with state health insurance scheme for
cashless tertiary care services for individuals belonging
to households below the poverty line
• Weak linkage among health system levels • Improved tracking of cases through the health
information system
Source: Tamil Nadu Health Systems Project, personal communication.
Abbreviation: NCD, noncommunicable disease.
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across the life course [21]. Research is needed to identify the
optimal way to implement cervical cancer prevention in India,
taking intoaccountcost,humanresources,and infrastructural
elements. For example, should cervical cancer screening be
packaged along with NCD prevention or family planning ser-
vices? What are the best entry points for HPV vaccination?
Data on cost and cost-effectiveness of primary and secondary
prevention strategies are also important to ensure that lim-
ited resources are used most strategically. Key stakeholders
such as program managers and policy makers should be en-
gaged in this process to ensure policy relevance.
With a quarter of the global burden of cervical cancer in In-
dia, there is no better time than now to translate research
findings into practice. Implementation science can help en-
sure that investments in cervical cancer prevention and con-
trol result in the greatest impact.
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